Added to YB: 2025-12-19
Pitch date: 2025-12-18
TMDX [bullish]
TransMedics Group, Inc.
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Market Cap
$4.3B
Pitch Price
N/A
Price Target
256.00 (+111%)
Dividend
N/A
EV/EBITDA
33.95
P/E
49.31
EV/Sales
7.64
Sector
Health Care Equipment and Supplies
Category
growth
Show full summary:
From Volume Expansion to Multiple Re-Rating: The TransMedics Opportunity
TMDX: Targeting 10k annual transplant cases by EOY28 at ~$103k/case = $1.03B revenue. 25%+ grower in expanding healthcare niche insulated from AI/tariff risks. Peers trade 7-10x sales; middle 8.8x = $256/share target. Mispriced due to analyst misfocus.
Read full article (1 min)